PAS 83:2012 gives detailed guidance to increase clarity for users on the requirements needed for exploitation of cell therapy products in the European Union and the US.

Who is this standard for?

Medical and healthcare manufacturers of any size

Developers of new cell therapy products

Academic groups

Anyone using cell-based products

Why should you use this standard?

It provides the latest guidelines and recommendations surrounding requirements for the development of human cells for clinical applications. Organizations are developing new treatments using human cells and researching their behaviour – this PAS will give guidance on the level of regulation, guidance and associated quality issues that apply to cell therapy products.

The main focus of this PAS is cell based medicinal products (CBMPs) that are regulated as advanced therapy medicinal products (ATMP) in the EU and biologics (351 HCT/P) in the US. However, for completeness aspects of minimally manipulated, homologous use products (also known as 361 HCT/P in the US) are also covered.

You might also be interested in:

Standard Number

PAS 83:2012

Title

Developing human cells for clinical applications in the European Union and the United States of America. Guide

Please note: You may experience issues viewing this site in Internet Explorer 9, 10 or 11. Please download Chrome or Firefox or view our browser tips.
This website is best viewed with browser version of up to Microsoft Internet Explorer 8 or Firefox 3.5.

We use cookies to make our website easier to use and to better understand your needs.